康缘药业: 江苏康缘药业股份有限公司第八届董事会第十九次临时会议决议公告

Core Points - Jiangsu Kangyuan Pharmaceutical Co., Ltd. held its 19th temporary meeting of the 8th Board of Directors on May 30, 2025, to discuss and approve key resolutions [1][2] - The board approved a proposal to change the legal representative from Chairman Xiao Wei to Director Gao Haixin, which complies with relevant laws and regulations [1][2] - The voting results for the proposal were unanimous, with 9 votes in favor and no votes against or abstentions [1] Summary by Sections Board Meeting Details - The meeting was notified on May 28, 2025, and conducted both in-person and via communication methods [1] - The meeting was presided over by Chairman Xiao Wei [1] Legal Representative Change - The change of the legal representative is in accordance with the Company Law of the People's Republic of China and the Shanghai Stock Exchange's self-regulatory guidelines [1] - The board authorized relevant personnel to handle the business registration change as per regulations [2] Profile of New Legal Representative - Gao Haixin, born in May 1988, holds a doctoral degree and has been with the company since 2014, serving in various roles [4] - As of the announcement date, Gao Haixin holds 60,000 shares of the company and has no conflicts of interest with other board members or significant shareholders [4]